Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Moffitt Cancer Center · University of Kentucky · +24 more institutions
Abstract
Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors.
Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here.
Citation impact
- FWCI
- 178.27
- Percentile
- 100%
- References
- 30
Authors
35- JSJonathan StrosbergCorresponding
Moffitt Cancer Center
- GEGhassan El‐Haddad
Moffitt Cancer Center
- EMEdward M. Wolin
University of Kentucky, Moffitt Cancer Center, Markey Cancer Center
- AHAndrew Hendifar
Moffitt Cancer Center, Cedars-Sinai Medical Center
- JCJames C. Yao
The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center
Topics & keywords
- Midgut
- Neuroendocrine tumors
- Medicine
- Somatostatin receptor
- Somatostatin
- Radionuclide therapy
- Internal medicine
- Somatostatin receptor 2
- Good health and well-being